Pranax: Funding, Investors & Team (Oct 2026)
Pranax is a biotechnology company that develops and commercializes regenerative medicine solutions centered on exosome technology licensed from leading research institutions to support tissue repair, immune modulation, and healthspan goals. Its work focuses on harnessing stem cell-derived exosomes as foundational biological agents that can be formulated into physician-directed supplements, therapeutic products, and personalized biological services designed to address inflammation, aging-associated decline, and tissue damage through evidence-based science. The company combines proprietary manufacturing methods with clinical and research insights to produce exosome-based offerings and to explore applications across wellness, longevity, and regenerative care. Pranax also provides exosome banking services that enable personalized collection and preservation of extracellular vesicles for potential future use in health programs. Its platform integrates advanced biological engineering with analytical frameworks to support translational research and product development in regenerative biology. The company engages scientific collaborators and technical teams to expand its portfolio of exosome-derived products and to investigate therapeutic pathways that leverage cellular communication mechanisms for improved biological function.
Pranax has raised $17.0M across 1 funding round on record, the most recent a Series A of $17.0M announced in Jan 2026.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Pranax Company Profile and Key Stats
Latest funding round on record: Jan 2026.
Pranax Funding Rounds
Pranax Founders and Leadership Team
No contact details are on record for this team yet.
Pranax Funding Compared to Other Biotechnology Startups
Pranax's latest round of $17.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Pranax in Biotechnology and Houston
Companies Similar to Pranax
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Pranax Funding FAQs
What does Pranax do?
Pranax is a biotechnology company that develops and commercializes regenerative medicine solutions centered on exosome technology licensed from leading research institutions to support tissue repair, immune modulation, and healthspan goals. Its work focuses on harnessing stem cell-derived exosomes as foundational biological agents that can be formulated into physician-directed supplements, therapeutic products, and personalized biological services designed to address inflammation, aging-associated decline, and tissue damage through evidence-based science. The company combines proprietary manufacturing methods with clinical and research insights to produce exosome-based offerings and to explore applications across wellness, longevity, and regenerative care. Pranax also provides exosome banking services that enable personalized collection and preservation of extracellular vesicles for potential future use in health programs. Its platform integrates advanced biological engineering with analytical frameworks to support translational research and product development in regenerative biology. The company engages scientific collaborators and technical teams to expand its portfolio of exosome-derived products and to investigate therapeutic pathways that leverage cellular communication mechanisms for improved biological function.
How much funding has Pranax raised?
Pranax has raised $17.0M across 1 round on record. The most recent is a Series A of $17.0M announced in Jan 2026.
When did Pranax last raise funding?
Pranax's most recent funding round on record is a Series A of $17.0M, announced in Jan 2026.
Who founded Pranax?
FundedIQ lists Steven J Greco (Founder) at Pranax.
Where is Pranax headquartered?
Pranax is based in Houston, Texas, United States.
How many employees does Pranax have?
Pranax is in the 11-50 employee band.
How does Pranax's funding compare to other Biotechnology startups?
Pranax's latest round of $17.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Pranax Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Pranax is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.